Article List
List all articles in the database by earliest discovery_date
GET /articles/?format=api&page=1345
{ "count": 24314, "next": "http://api.gregory-ms.com/articles/?format=api&page=1346", "previous": "http://api.gregory-ms.com/articles/?format=api&page=1344", "results": [ { "article_id": 439506, "title": "Vestibular click-evoked myogenic potentials: sensitivity and factors determining abnormality in patients with multiple sclerosis", "summary": "<jats:p> Vestibular evoked myogenic potential (VEMP) assesses the sacculo-spinal pathway. The aim of our study was to examine sensitivity and factors determining abnormality of VEMP, indicative of brainstem dysfunction, in patients with multiple sclerosis (MS). Thirty healthy subjects and 30 MS patients were examined. All healthy subjects showed a normal biphasic response. Twelve of the 30 MS patients (40%) had abnormal recordings. There was a significant difference between MS patients and control subjects with respect to P13 latency (longer in the MS group) and P13-N23 amplitude (lower in the MS group). VEMP abnormalities were statistically significantly related to the presence of brainstem demyelinative lesions and a weaker correlation was found with disease duration. Clinical signs of vestibular dysfunction at any point during the course of the disease did not seem to affect the chances of obtaining abnormal VEMPs. Although the sensitivity of VEMP in detecting abnormality in MS patients is relatively low, its significance is evident in that it is the only electrophysiological method that is able to detect dysfunction in central vestibular pathways. Multiple Sclerosis 2007; 13: 193–198. http://msj.sagepub.com </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1177/1352458506070940", "published_date": "2007-03-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 307054, "given_name": "T", "family_name": "Patkó", "ORCID": null, "country": null }, { "author_id": 307055, "given_name": "M", "family_name": "Simó", "ORCID": null, "country": null }, { "author_id": 307056, "given_name": "Z", "family_name": "Arányi", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:10.232653Z", "noun_phrases": [ "Vestibular click-evoked myogenic potentials", "sensitivity", "factors", "abnormality", "patients", "multiple sclerosis" ], "doi": "10.1177/1352458506070940", "access": "restricted", "takeaways": " VEMP is the only electrophysiological method that is able to detect dysfunction in central vestibular pathways . VEMP abnormalities were statistically significantly related to the presence of brainstem demyelinative lesions and a weaker correlation was found with disease duration .", "categories": [] }, { "article_id": 439505, "title": "Screening for depression among patients with multiple sclerosis: two questions may be enough", "summary": "<jats:sec><jats:title>Background</jats:title><jats:p> Depression among patients with multiple sclerosis (MS) is common and has a significant impact on quality of life. As many as two-thirds of depressed MS patients receive no treatment for their depression. While guidelines for depression management suggest screening, the only validated screening tools are questionnaires, which have not been widely implemented in practice. This is the first study on the effectiveness of using two questions assessing mood and anhedonia (loss of interest or pleasure) in screening for major depressive disorder (MDD) in MS. </jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p> MS patients under the care of neurologists were recruited from a large health maintenance organization (HMO). The MDD module of the Structured Clinical Interview for the DSM-IV and screening questions was administered. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Of the 260 participants, 26% met the criteria for MDD. Among patients with MDD, 67% received no anti-depressant medication. The MDD screen identified 99% (95% CI: 91–100%) of cases. </jats:p></jats:sec><jats:sec><jats:title>Discussion</jats:title><jats:p> A brief, two question screen is reliable in identifying MS patients with MDD. This suggests that asking these two brief questions could identify almost all MS patients meeting MDD criteria, with minimal numbers of false positives. Multiple Sclerosis 2007; 13: 215–219. http://msj.sagepub.com </jats:p></jats:sec>", "link": "https://journals.sagepub.com/doi/pdf/10.1177/1352458506070926", "published_date": "2007-03-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 260213, "given_name": "Dc", "family_name": "Mohr", "ORCID": null, "country": null }, { "author_id": 260214, "given_name": "Sl", "family_name": "Hart", "ORCID": null, "country": null }, { "author_id": 260215, "given_name": "L", "family_name": "Julian", "ORCID": null, "country": null }, { "author_id": 260216, "given_name": "Es", "family_name": "Tasch", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:10.231544Z", "noun_phrases": [ "depression", "patients", "multiple sclerosis", "two questions" ], "doi": "10.1177/1352458506070926", "access": "restricted", "takeaways": " Depression among patients with multiple sclerosis is common and has a significant impact on quality of life . As many as two-thirds of depressed MS patients receive no treatment for their depression . This is the first study on the effectiveness of using two questions assessing mood and anhedonia in screening for major depressive disorder in MS .", "categories": [] }, { "article_id": 439504, "title": "Stress regulation in multiple sclerosis – current issues and concepts", "summary": "<jats:p> Since its first description by Charcot, psychological stress has been considered a triggering factor for exacerbations in multiple sclerosis, but until recently the clinical evidence for a causal relation was weak. Over the past years, a growing number of studies have started to elucidate this association and highlight potential mechanisms, including brain-immune communication. On 5 June 2005, a panel of international researchers discussed the current evidence. This article summarizes the observational, animal experimental, as well as human experimental findings on stress regulation in MS, as well as studies on the functioning of the major stress response systems, ie, the hypothalamo-pituitary-adrenal (HPA) axis and the autonomous nervous system (ANS) in MS. Consensus statements from the group to these aspects are given. Research objectives and strategies are delineated, as well as clinical implications. Multiple Sclerosis 2007; 13: 143–148. http://msj.sagepub.com </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1177/1352458506070772", "published_date": "2007-03-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 244838, "given_name": "C", "family_name": "Heesen", "ORCID": null, "country": null }, { "author_id": 260213, "given_name": "Dc", "family_name": "Mohr", "ORCID": null, "country": null }, { "author_id": 296698, "given_name": "I", "family_name": "Huitinga", "ORCID": null, "country": null }, { "author_id": 296699, "given_name": "F Then", "family_name": "Bergh", "ORCID": null, "country": null }, { "author_id": 296700, "given_name": "J", "family_name": "Gaab", "ORCID": null, "country": null }, { "author_id": 296701, "given_name": "C", "family_name": "Otte", "ORCID": null, "country": null }, { "author_id": 296702, "given_name": "Sm", "family_name": "Gold", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:10.230511Z", "noun_phrases": [ "Stress regulation", "multiple sclerosis", "current issues", "concepts" ], "doi": "10.1177/1352458506070772", "access": "restricted", "takeaways": " Psychological stress has been considered a triggering factor for exacerbations in multiple sclerosis . Until recently the clinical evidence for a causal relation was weak . Growing number of studies have started to elucidate this association and highlight potential mechanisms, including brain-immune communication .", "categories": [] }, { "article_id": 439503, "title": "Epidemiology of familial multiple sclerosis in Hungary", "summary": "<jats:p> The prevalence of familial aggregation of multiple sclerosis (MS) is estimated between 5 and 10%. Studies emphasize the effect of genetic factors over the environment of the patients in the development of the disease. We investigated familial accumulation of MS in the cases of 1500 patients in five Hungarian MS centers. According to our data, the risk of familial MS in Hungary is lower than in other countries for which literature data are accessible. The literature does not contain any data for the prevalence of familial MS in Hungary and middle-eastern Europe. Multiple Sclerosis 2007; 13: 260–261. http://msj.sagepub.com </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1177/1352458506070767", "published_date": "2007-03-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 294175, "given_name": "Z", "family_name": "Fricska-Nagy", "ORCID": null, "country": null }, { "author_id": 245484, "given_name": "K", "family_name": "Bencsik", "ORCID": null, "country": null }, { "author_id": 245483, "given_name": "C", "family_name": "Rajda", "ORCID": null, "country": null }, { "author_id": 245485, "given_name": "J", "family_name": "Füvesi", "ORCID": null, "country": null }, { "author_id": 294176, "given_name": "V", "family_name": "Honti", "ORCID": null, "country": null }, { "author_id": 294177, "given_name": "T", "family_name": "Csépány", "ORCID": null, "country": null }, { "author_id": 294178, "given_name": "E", "family_name": "Dobos", "ORCID": null, "country": null }, { "author_id": 294179, "given_name": "K", "family_name": "Mátyás", "ORCID": null, "country": null }, { "author_id": 294180, "given_name": "C", "family_name": "Rózsa", "ORCID": null, "country": null }, { "author_id": 294181, "given_name": "S", "family_name": "Komoly", "ORCID": null, "country": null }, { "author_id": 245487, "given_name": "L", "family_name": "Vécsei", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:10.229708Z", "noun_phrases": [ "Epidemiology", "familial multiple sclerosis", "Hungary" ], "doi": "10.1177/1352458506070767", "access": "restricted", "takeaways": " The prevalence of familial aggregation of multiple sclerosis (MS) is estimated between 5 and 10% . The risk of familial MS in Hungary is lower than in other countries for which literature data are accessible .", "categories": [] }, { "article_id": 439502, "title": "Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity", "summary": "<jats:p> Development of neutralizing antibodies (NAbs) reduces the clinical efficacy of interferon beta (IFNβ) treatment in multiple sclerosis (MS) patients. The aim of this study was to evaluate NAb seroprevalence (frequency of patients with NAbs) and immunogenicity (titer levels) of IFNβ preparations in a clinical setting. We analysed 1115 consecutive MS patients, treated with one of the three available IFNβ preparations, for an average of 40 months (1 – 120 months), for the presence of NAbs with the MxA protein induction assay. Overall, 32% of patients were positive for NAbs with neutralizing titers above 10. The frequency of NAbs, ie, the seroprevalence, was 13% in Avonex-treated patients, 43% for Betaferon, 39% for Rebif22 and 30% for Rebif44. In addition, the potential to induce high titer levels, ie, the immunogenicity, was observed to differ between preparations. Avonex, showing the lowest seroprevalence, also showed low immunogenicity and typically induced low titers. Betaferon, showing the highest seroprevalence when inducing NAbs, induced lower titers compared to Rebif22 and Rebif44. Treatment duration over five years only marginally correlated with decreased seroprevalence and titer levels. </jats:p><jats:p> In conclusion, NAbs to IFNβ are common in a clinical setting and the IFNβ preparations differ not only in NAb seroprevalence, but also in immunogenicity. Multiple Sclerosis 2007; 13: 208–214. http://msj.sagepub.com </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1177/1352458506070762", "published_date": "2007-03-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 253596, "given_name": "A", "family_name": "Sominanda", "ORCID": null, "country": null }, { "author_id": 253597, "given_name": "U", "family_name": "Rot", "ORCID": null, "country": null }, { "author_id": 253598, "given_name": "M", "family_name": "Suoniemi", "ORCID": null, "country": null }, { "author_id": 247854, "given_name": "F", "family_name": "Deisenhammer", "ORCID": null, "country": null }, { "author_id": 245908, "given_name": "J", "family_name": "Hillert", "ORCID": null, "country": null }, { "author_id": 253599, "given_name": "A", "family_name": "Fogdell-Hahn", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:10.228879Z", "noun_phrases": [ "Interferon beta preparations", "the treatment", "multiple sclerosis patients", "neutralizing antibody seroprevalence", "immunogenicity" ], "doi": "10.1177/1352458506070762", "access": "restricted", "takeaways": " Development of neutralizing antibodies (NAbs) reduces clinical efficacy of interferon beta (IFNβ) treatment in MS patients . Avonex showed the lowest seroprevalence and Betaferon showed the highest immunogenicity when inducing NAbs . NAbs to IFNβ are common in a clinical setting .", "categories": [] }, { "article_id": 439501, "title": "Relationship of triple dose contrast enhanced lesions with clinical measures and brain atrophy in early relapsing-remitting multiple sclerosis: a two-year longitudinal study", "summary": "<jats:p> Gadolinium (Gd) enhancement of lesions indicates inflammatory lesion activity in multiple sclerosis (MS). The question arises whether early inflammatory lesion activity – measured sensitively using triple dose Gd – is related to the future clinical course, or to the development of brain atrophy that is thought to reflect the underlying pathological progression of the disease. In this study, 26 patients with early relapsing-remitting (RR) MS (median disease duration: 1.7 years) were followed up over two years. Associations were explored between their levels of Gd-lesion enhancement in the first six months and later clinical (Expanded Disability Status Scale (EDSS) and MS Functional Composite Score (MSFC)) and magnetic resonance imaging (MRI) (brain volume, T<jats:sub>2</jats:sub> and T<jats:sub>1</jats:sub> lesion volumes) measures. The extent of Gd-enhancement in the first six months correlated weakly with concurrent relapses (P = 0.041), but there was no consistent correlation with clinical and MRI outcomes at two years. More prolonged follow-up is warranted to clarify the relationship between early inflammatory lesions and long-term clinical course. Multiple Sclerosis 2007; 13: 178–185. http://msj.sagepub.com </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1177/1352458506070758", "published_date": "2007-03-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 246428, "given_name": "W", "family_name": "Rashid", "ORCID": null, "country": null }, { "author_id": 246429, "given_name": "Gr", "family_name": "Davies", "ORCID": null, "country": null }, { "author_id": 246431, "given_name": "Dt", "family_name": "Chard", "ORCID": null, "country": null }, { "author_id": 246432, "given_name": "Cm", "family_name": "Griffin", "ORCID": null, "country": null }, { "author_id": 246434, "given_name": "DR", "family_name": "Altmann", "ORCID": null, "country": null }, { "author_id": 246435, "given_name": "Aj", "family_name": "Thompson", "ORCID": null, "country": null }, { "author_id": 246437, "given_name": "Dh", "family_name": "Miller", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:10.228062Z", "noun_phrases": [ "Relationship", "triple dose contrast", "enhanced lesions", "clinical measures", "brain atrophy", "early relapsing-remitting multiple sclerosis", "a two-year longitudinal study" ], "doi": "10.1177/1352458506070758", "access": "restricted", "takeaways": " Gadolinium (Gd) enhancement of lesions indicates inflammatory lesion activity in MS . 26 patients with early relapsing-remitting (RR) MS (median disease duration: 1.7 years) followed up over two years .", "categories": [] }, { "article_id": 439500, "title": "Predictors of well-being among significant others of persons with multiple sclerosis", "summary": "<jats:sec><jats:title>Objective</jats:title><jats:p> To examine patient and significant other characteristics as predictors of significant other well-being. </jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p> A total of 74 persons with multiple sclerosis (MS) and their significant others participated. Executive functioning was measured using neuropsychological tests. Awareness of cognitive deficit was measured as the discrepancy between the patient's reports of their abilities and objective test results. Awareness of functional deficit was measured as the discrepancy between the patient's and significant other's reports of the patient's functional abilities. Patient neurobehavioral disturbance was measured using a significant-other rated questionnaire. Significant other perceived social support and well-being (ie, psychological distress, life satisfaction, and general health status) were assessed using questionnaires filled out by the significant other. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Executive dysfunction, neurobehavioral disturbance, and lack of awareness of functional deficits in patients were associated with poor well-being outcomes; whereas, lack of awareness of cognitive deficits was only weakly related to well-being. Social support was associated with positive well-being outcomes. </jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p> Diminished insight regarding functional limitations may increase significant others’ supervisory burden as patients attempt activities independently, whereas lack of awareness of cognitive deficits may not be directly associated with behavior-relevant impairments that significant others find distressing. Social support appears to be a powerful aid in diffusing the distress among significant others of MS patients. Multiple Sclerosis 2007; 13: 238–249. http://msj.sagepub.com </jats:p></jats:sec>", "link": "https://journals.sagepub.com/doi/pdf/10.1177/1352458506070754", "published_date": "2007-03-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 276708, "given_name": "Te", "family_name": "Sherman", "ORCID": null, "country": null }, { "author_id": 276710, "given_name": "Lj", "family_name": "Rapport", "ORCID": null, "country": null }, { "author_id": 276712, "given_name": "Ra", "family_name": "Hanks", "ORCID": null, "country": null }, { "author_id": 276714, "given_name": "Ka", "family_name": "Ryan", "ORCID": null, "country": null }, { "author_id": 276715, "given_name": "Pa", "family_name": "Keenan", "ORCID": null, "country": null }, { "author_id": 244080, "given_name": "O", "family_name": "Khan", "ORCID": null, "country": null }, { "author_id": 276716, "given_name": "Rp", "family_name": "Lisak", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:10.226917Z", "noun_phrases": [ "Predictors", "significant others", "persons", "multiple sclerosis" ], "doi": "10.1177/1352458506070754", "access": "restricted", "takeaways": " Executive functioning was measured using neuropsychological tests . Awareness of cognitive deficit was measured as the discrepancy between the patient's and significant other's reports of their abilities and objective test results . Significant other perceived social support and well-being were assessed using questionnaires filled out by the significant other .", "categories": [] }, { "article_id": 439499, "title": "Immunosuppressive therapy is more effective than interferon in neuromyelitis optica", "summary": "<jats:p> To determine long-term treatment (LTT) of neuromyelitis optica (NMO), we retrospectively reviewed therapies of 26 patients with NMO followed in five French neurological departments. To assess LTT efficacy, the probability of relapse free after LTT was analysed. Patients were divided into two groups according to the first treatment receiving interferon beta (IFN Group, seven patients) or immunosuppressants (IS Group, 19 patients). The probability of relapse was significantly lower in the IS Group (P = 0.0007). From our results, interferon beta is not recommended, and one of the best current therapeutic options for NMO appears to be immunosuppressants. Multiple Sclerosis 2007; 13: 256–259. http://msj.sagepub.com </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1177/1352458506070732", "published_date": "2007-03-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 253486, "given_name": "C", "family_name": "Papeix", "ORCID": null, "country": null }, { "author_id": 301625, "given_name": "J-S", "family_name": "Vidal", "ORCID": null, "country": null }, { "author_id": 301626, "given_name": "J De", "family_name": "Seze", "ORCID": null, "country": null }, { "author_id": 301627, "given_name": "C", "family_name": "Pierrot-Deseilligny", "ORCID": null, "country": null }, { "author_id": 253488, "given_name": "A", "family_name": "Tourbah", "ORCID": null, "country": null }, { "author_id": 253489, "given_name": "B", "family_name": "Stankoff", "ORCID": null, "country": null }, { "author_id": 242045, "given_name": "C", "family_name": "Lebrun", "ORCID": null, "country": null }, { "author_id": 247164, "given_name": "T", "family_name": "Moreau", "ORCID": null, "country": null }, { "author_id": 250464, "given_name": "P", "family_name": "Vermersch", "ORCID": null, "country": null }, { "author_id": 301628, "given_name": "B", "family_name": "Fontaine", "ORCID": null, "country": null }, { "author_id": 298924, "given_name": "O", "family_name": "Lyon-Caen", "ORCID": null, "country": null }, { "author_id": 301629, "given_name": "O", "family_name": "Gout", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:10.225586Z", "noun_phrases": [ "Immunosuppressive therapy", "interferon", "neuromyelitis optica" ], "doi": "10.1177/1352458506070732", "access": "restricted", "takeaways": " The probability of relapse was significantly lower in the IS Group (P = 0.0007) From our results, interferon beta is not recommended, and one of the best current therapeutic options for NMO appears to be immunosupp", "categories": [] }, { "article_id": 439498, "title": "Effects of motor cortex rTMS on lower urinary tract dysfunction in multiple sclerosis", "summary": "<jats:p> We tested the effects of 5-Hz rTMS over the motor cortex in multiple sclerosis (MS) subjects complaining of lower urinary tract symptoms either in the filling or voiding phase. Our data show that motor cortex stimulation for five consecutive days over two weeks ameliorates the voiding phase of the micturition cycle, suggesting that enhancing corticospinal tract excitability might be useful to ameliorate detrusor contraction and/or urethral sphincter relaxation in MS patients with bladder dysfunction. Multiple Sclerosis 2007; 13: 269–271. http://msj.sagepub.com </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1177/1352458506070729", "published_date": "2007-03-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 256195, "given_name": "D", "family_name": "Centonze", "ORCID": null, "country": null }, { "author_id": 276501, "given_name": "F", "family_name": "Petta", "ORCID": null, "country": null }, { "author_id": 276502, "given_name": "V", "family_name": "Versace", "ORCID": null, "country": null }, { "author_id": 256186, "given_name": "S", "family_name": "Rossi", "ORCID": null, "country": null }, { "author_id": 276505, "given_name": "F", "family_name": "Torelli", "ORCID": null, "country": null }, { "author_id": 276506, "given_name": "C", "family_name": "Prosperetti", "ORCID": null, "country": null }, { "author_id": 276507, "given_name": "St", "family_name": "Rossi", "ORCID": null, "country": null }, { "author_id": 276508, "given_name": "Ga", "family_name": "Marfia", "ORCID": null, "country": null }, { "author_id": 276509, "given_name": "G", "family_name": "Bernardi", "ORCID": null, "country": null }, { "author_id": 276510, "given_name": "G", "family_name": "Koch", "ORCID": null, "country": null }, { "author_id": 276511, "given_name": "R", "family_name": "Miano", "ORCID": null, "country": null }, { "author_id": 276512, "given_name": "L", "family_name": "Boffa", "ORCID": null, "country": null }, { "author_id": 276513, "given_name": "E", "family_name": "Finazzi-Agrò", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:10.224489Z", "noun_phrases": [ "Effects", "motor cortex rTMS", "lower urinary tract dysfunction", "multiple sclerosis" ], "doi": "10.1177/1352458506070729", "access": "restricted", "takeaways": " We tested the effects of 5-Hz rTMS over the motor cortex in multiple sclerosis (MS) subjects complaining of lower urinary tract symptoms either in the filling or voiding phase .", "categories": [] }, { "article_id": 439497, "title": "Normal-appearing grey and white matter T1 abnormality in early relapsing–remitting multiple sclerosis: a longitudinal study", "summary": "<jats:sec><jats:title>Objective</jats:title><jats:p> To investigate the presence and evolution of T<jats:sub>1</jats:sub> relaxation time abnormalities in normal-appearing white matter (NAWM) and grey matter (GM), early in the course of relapsing–remitting multiple sclerosis (MS). </jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p> Twenty-three patients with early relapsing–remitting MS and 14 healthy controls were imaged six monthly for up to three years. Mean follow-up was 26 months for MS patients and 24 months for controls. Dual-echo fast-spin echo and gradient-echo proton-density and T<jats:sub>1</jats:sub>-weighted data sets (permitting the calculation of a T<jats:sub>1</jats:sub> map) were acquired in all subjects. GM and NAWM T<jats:sub>1</jats:sub> histograms were produced and a hierarchical regression model was used to investigate changes in T<jats:sub>1</jats:sub> over time. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> At baseline, significant patient-control differences were seen, both in NAWM (P = 0.001) and in GM (P = 0.01). At follow-up, there was no evidence for a serial change in either mean T<jats:sub>1</jats:sub> or peak-location for either NAWM or GM. There was weak evidence for a decline in patient NAWM peak-height and also evidence for a decline in control GM peak-height. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> There are significant and persistent abnormalities of NAWM and GM T<jats:sub>1</jats:sub> in early relapsing-remitting MS. Further studies should address whether such T<jats:sub>1</jats:sub> measures have a role in prognosis or therapeutic monitoring. Multiple Sclerosis 2007; 13:169–177. http://msj.sagepub.com </jats:p></jats:sec>", "link": "https://journals.sagepub.com/doi/pdf/10.1177/1352458506070726", "published_date": "2007-03-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 246429, "given_name": "Gr", "family_name": "Davies", "ORCID": null, "country": null }, { "author_id": 254558, "given_name": "A", "family_name": "Hadjiprocopis", "ORCID": null, "country": null }, { "author_id": 246434, "given_name": "DR", "family_name": "Altmann", "ORCID": null, "country": null }, { "author_id": 246431, "given_name": "Dt", "family_name": "Chard", "ORCID": null, "country": null }, { "author_id": 246432, "given_name": "Cm", "family_name": "Griffin", "ORCID": null, "country": null }, { "author_id": 246428, "given_name": "W", "family_name": "Rashid", "ORCID": null, "country": null }, { "author_id": 284240, "given_name": "Gj", "family_name": "Parker", "ORCID": null, "country": null }, { "author_id": 284242, "given_name": "Ps", "family_name": "Tofts", "ORCID": null, "country": null }, { "author_id": 251678, "given_name": "R", "family_name": "Kapoor", "ORCID": null, "country": null }, { "author_id": 246435, "given_name": "Aj", "family_name": "Thompson", "ORCID": null, "country": null }, { "author_id": 246437, "given_name": "Dh", "family_name": "Miller", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:10.223619Z", "noun_phrases": [ "Normal-appearing grey", "white matter T1 abnormality", "early relapsing", "multiple sclerosis", "a longitudinal study" ], "doi": "10.1177/1352458506070726", "access": "restricted", "takeaways": " Twenty-three patients with early relapsing–remitting MS and 14 healthy controls were imaged six monthly for up to three years . At baseline, significant patient-control differences were seen, both in NAWM and in GM . At follow-up, there was no evidence for a serial change in either mean T1 or peak-location for either NAWM or GM .", "categories": [] } ] }